

<i>cis-</i>	Accutane; Isotrex; Ro-4-3780; Roaccutan; Roaccutane			
	Roche Ro- 40-0655	Roche Holdings		
	Roche Ro- 25-6760	Roche Holdings		
	Roche Ro- 25-9022	Roche Holdings		
	Roche Ro- 25-9716	Roche Holdings		
Benzoic acid, 4- [[3,5- bis(trimeth- ylsilyl)ben- zoyl]amino] -	TAC-101	Taiho Pharmace- utical		
Retinamide, N-(4- hydroxyphen- yl)-	fenretinid e 4-HPR; HPR; McN- R-1967			50 - 400 mg/kg/day
(2E,4E,6E)- 7-(3,5-Di-	LGD-1550 ALRT-1550;	Ligand Pharma-		20 microg/m2

tert- butylphenyl) -3- methylocta- 2,4,6- triеноic acid	ALRT-550; LG-1550	ceuticas ; Allergan USA		/day to 400 microg/m ² /day administe red as a single daily oral dose
	Molecular Design MDI-101		US 4885311	
	Molecular Design MDI-403		US 4677120	
Benzoic acid, 4-(1- (5,6,7,8- tetrahydro- 3,5,5,8,8- pentamethyl -2- naphthaleny l)eth enyl)-	bexarotene LG-1064; LG-1069; LGD-1069; Targretin; Targretin Oral; Targretin Topical Gel		WO 94/15901	
Benzoic acid, 4-(1- (5,6,7,8- tetrahydro- 3,5,8,8-	bexarotene , soft gel bexarotene , Ligand; bexaroten	R P Scherer		

pentamethyl -2- naphthaleny l)ethen yl)-				
(2E, 4E)-3- methyl-5- [3- (5,5,8,8- tetramethyl -5,6,7,8- tetrahydro- naphthalen- 2-yl)- thiopen-2- yl]-penta- 2,4-dienoic acid			WO 96/05165	
	SR-11262 F	Hoffmann -La Roche Ltd		
	BMS-181162	Bristol Myers Squibb	EP 476682	
N-(4- hydroxyphen yl)retinami de	IIT Research Institute		Cancer Research 39, 1339- 1346 (1979)	